. 2015 Apr;17().
doi: 10.1186/s13058-015-0559-2.

The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy

François Bertucci 1 Pascal Finetti 1 Daniel Birnbaum 1 
  • PMID: 25887620
  •     5 References
  •     2 citations

No abstract available

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
Cornelia Liedtke, Christos Hatzis, +8 authors, Lajos Pusztai.
J Clin Oncol, 2009 Apr 15; 27(19). PMID: 19364972    Free PMC article.
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.
Michael Knauer, Stella Mook, +7 authors, Laura J van 't Veer.
Breast Cancer Res Treat, 2010 Mar 06; 120(3). PMID: 20204499
EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
François Bertucci, Pascal Finetti, Patrice Viens, Daniel Birnbaum.
Cancer Lett, 2014 Sep 15; 355(1). PMID: 25218596
E2F4 regulatory program predicts patient survival prognosis in breast cancer.
Sari S Khaleel, Erik H Andrews, +2 authors, Chao Cheng.
Breast Cancer Res, 2014 Dec 03; 16(6). PMID: 25440089    Free PMC article.
Integrative Genomic Analyses Yield Cell-Cycle Regulatory Programs with Prognostic Value.
Chao Cheng, Shaoke Lou, +2 authors, Frederick S Varn.
Mol Cancer Res, 2016 Feb 10; 14(4). PMID: 26856934    Free PMC article.
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.
Kenneth M K Mark, Frederick S Varn, +2 authors, Chao Cheng.
BMC Cancer, 2017 May 04; 17(1). PMID: 28464832    Free PMC article.